![](https://endpts.com/wp-content/uploads/2020/04/sGettyImages-1192157964-scaled.jpg)
Stéphane Bancel (Photo by Steven Ferdman/Getty Images)
Moderna’s once high-flying stock buckles under the weight of a biotech rout. Is it cheap yet?
Last fall, with the world grappling — not all that well — with a global pandemic, anything might have seemed possible for the newly minted billionaires running …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.